Intraperitoneal mRNA-LNP Programming of CAR Macrophages in Cancer

Study Background and Research Question

Peritoneal metastasis represents a formidable clinical challenge in the management of advanced solid tumors. Traditional interventions, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, benefit only a subset of patients with minimal tumor burden, leaving the majority without effective options (paper). Immunotherapy, particularly modalities that can overcome the immunosuppressive tumor microenvironment, is a promising frontier. Macrophages—comprising nearly half of the immune cell population in peritoneal ascites—offer unique potential for therapeutic reprogramming. However, systematic evaluation of chimeric antigen receptor (CAR) designs and mechanisms for empowering macrophages against solid tumors remains an unmet need.

Key Innovation from the Reference Study

Gu et al. introduce a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) platform for intraperitoneal programming of tailored CAR macrophages (CAR-Ms) directly within the peritoneal cavity. This approach enables rapid, in situ generation of CAR-Ms without ex vivo manipulation, addressing both practical and immunological barriers to cell therapy in solid tumors. The study systematically screens 36 CAR constructs to optimize intracellular signaling domains (ICDs) for maximal antitumor efficacy, identifying combinations that significantly enhance adaptive immune responses and synergize with immune checkpoint blockade (paper).

Methods and Experimental Design Insights

The research employs a multi-pronged experimental strategy:

• Development and characterization of a macrophage-specific mRNA-LNP system for in vivo delivery.
• Systematic design and screening of 36 CAR constructs, each incorporating different ICDs relevant to macrophage activation.
• In vivo administration of mRNA-LNPs via the intraperitoneal route in mouse models of peritoneal metastasis.
• Functional and phenotypic analyses using single-cell RNA sequencing (scRNA-seq), flow cytometry, and immunohistochemistry to monitor CAR expression, TME remodeling, and immune cell dynamics.
• Synergy assessment with PD-1/L1 immune checkpoint therapy.

Bioluminescence imaging, utilizing firefly luciferase substrate systems such as D-Luciferin sodium salt, is employed for non-invasive monitoring of CAR-M viability, localization, and antitumor activity—a workflow aligning with best practices highlighted in recent translational research (internal article).

Core Findings and Why They Matter

The study yields several important discoveries:

• Optimal CAR design: CAR-Ms incorporating CD3ζ and TLR4 ICDs induce potent proinflammatory phenotypes, robustly activating both innate and adaptive immune responses (paper).
• Synergy with checkpoint blockade: Tailored CAR-Ms, when combined with PD-1/L1 therapy, significantly expand TCF1+PD-1+ progenitor-exhausted CD8+ T cell populations (Tpex), which are critical for durable antitumor immunity.
• TME remodeling: Single-cell transcriptomics reveal CAR-Ms reshape the immunosuppressive tumor microenvironment by upregulating MHC-I and PDL1 and modulating NF-κB signaling pathways, supporting antigen presentation and T cell reinvigoration.

Collectively, these findings demonstrate that mRNA-LNP programming enables a flexible, scalable approach to generating therapeutic macrophages tailored for solid tumor microenvironments—a significant advance over traditional ex vivo cell engineering methods.

Comparison with Existing Internal Articles

The mechanistic insights and workflow strategies reported by Gu et al. intersect with themes in several recent literature-focused resources:

• D-Luciferin Sodium Salt: Illuminating Translational Oncology describes the pivotal role of D-Luciferin sodium salt as a firefly luciferase substrate in non-invasive bioluminescence imaging, particularly for monitoring CAR macrophage viability and metabolic activity during in vivo studies. The current study's imaging protocols exemplify these translational applications.
• Illuminating the Path from Mechanism to Medicine further contextualizes how ATP-dependent bioluminescence assays, underpinned by high-purity D-Luciferin, drive sensitive assessment of cellular metabolism and therapeutic efficacy in preclinical immunotherapy models—directly paralleling Gu et al.'s experimental workflow.
• Intraperitoneal mRNA-LNP Programming of CAR Macrophages offers a focused overview of the mRNA-LNP platform, reinforcing the novelty and translational impact of in situ immune cell programming for peritoneal metastasis.

These internal articles collectively underscore the importance of robust bioluminescent substrate selection and protocol optimization for reliable cell viability and metabolism monitoring—a principle that underpins the reference study's methodology.

Protocol Parameters

• bioluminescence imaging substrate | 150 mg/kg (mouse, IP injection) | in vivo tracking of luciferase-expressing CAR-Ms | Enables sensitive monitoring of cell viability and localization within the peritoneal cavity | paper
• luciferase imaging time point | 10–20 min post-substrate injection | optimal signal-to-background ratio | Captures peak ATP-dependent bioluminescent signal for quantitative imaging | workflow_recommendation
• D-Luciferin sodium salt solution | freshly prepared in PBS, pH 7.4 | maintains substrate stability for consistent imaging | Prevents degradation and ensures reproducibility in ATP-dependent bioluminescence assays | workflow_recommendation

Limitations and Transferability

While the intraperitoneal mRNA-LNP platform demonstrates remarkable efficacy in preclinical mouse models, several limitations merit consideration:

• Species-specific immune responses may influence the translation of CAR-M programming strategies to human patients (paper).
• The safety and persistence of mRNA-LNP-modified macrophages in humans require further investigation, as do the long-term effects on immune homeostasis.
• Technological scalability for clinical-grade mRNA-LNP production and delivery remains an active area of development.

Nonetheless, the platform's modularity and ability to rapidly test CAR designs in situ highlight its potential for broader applications in solid tumor immunotherapy.

Research Support Resources

Researchers seeking to replicate or extend these workflows can leverage validated reagents for ATP-dependent bioluminescence assays. For example, D-Luciferin sodium salt (SKU B8311) is widely used as a firefly luciferase substrate for non-invasive imaging of cell viability, metabolic activity, and gene expression in CAR macrophage studies and related immuno-oncology models (internal article). APExBIO’s D-Luciferin sodium salt offers high solubility in water and DMSO, facilitating reproducible imaging protocols. For optimal experimental outcomes, solutions should be freshly prepared and used promptly to maintain substrate integrity. This approach supports sensitive, quantitative assessment of cellular energy metabolism and therapeutic efficacy in preclinical research.